The U.K. Medicines and Healthcare Products Regulatory Agency on Thursday recalled five prescription drugs, including the diabetes drug Gliclazide, from India's Wockhardt after discovering manufacturing deficiencies at the company's facility in India. "There is no evidence that the medicines affected by the precautionary recall in the U.K. are defective," the agency said. Wockhardt will still be allowed to continue its exports of 10 prescription medicines because not all drug imports have been banned from the facility, the agency said.
Published in Brief: